Committee for Orphan Medicinal Products (COMP): 10-12 September 2019, Amsterdam - Main contents
| date | September 10, 2019 - September 12, 2019 |
|---|---|
| city | Amsterdam |
| organisation | European Medicines Agency (EMA) i |
The Committee for Orphan Medicinal Products (COMP) is the committee that is responsible for reviewing applications for 'orphan medicinal product designation' for medicines intended for the diagnosis, prevention or treatment of rare diseases.
The European Medicines Agency (EMA) is a decentralised body of the European Union with headquarters in Amsterdam. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.
The EMA is responsible for the scientific evaluation of applications for European marketing authorisation for medicinal products (centralised procedure). Under the centralised procedure, companies submit one single marketing authorisation application to the EMA.